Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
40.29
+0.74 (1.87%)
Oct 29, 2025, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 609 employees as of September 30, 2024. The number of employees increased by 84 or 16.00% compared to the previous year.
Employees
609
Change (1Y)
84
Growth (1Y)
16.00%
Revenue / Employee
$940,847
Profits / Employee
-$243,706
Market Cap
5.57B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 609 | 84 | 16.00% |
| Sep 30, 2023 | 525 | 128 | 32.24% |
| Sep 30, 2022 | 397 | 68 | 20.67% |
| Sep 30, 2021 | 329 | 97 | 41.81% |
| Sep 30, 2020 | 232 | 98 | 73.13% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARWR News
- 1 day ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 9 days ago - Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis - Business Wire
- 23 days ago - Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Business Wire
- 4 weeks ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 7 weeks ago - Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha